Overview

Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of DA-302168S Tablets

Status:
COMPLETED
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
To Evaluate the Safety, Tolerability and Pharmacokinetics on DA-302168S Tablets in Randomized, Double-blind, Placebo-controlled Single-dose and Multiple-dose ascending Phase I Clinical Trials in Healthy Subjects.
Phase:
PHASE1
Details
Lead Sponsor:
Chendu DIAO Pharmaceutical Group CO., LTD.